Cargando…

A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma

BACKGROUND: In metastatic urothelial carcinoma (mUC), predictive biomarkers that correlate with response to immune checkpoint inhibitors (ICIs) are lacking. Here, we interrogated genomic and clinical features associated with response to ICIs in mUC. METHODS: Sixty two mUC patients treated with ICI w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nassar, Amin H., Mouw, Kent W., Jegede, Opeyemi, Shinagare, Atul B., Kim, Jaegil, Liu, Chia-Jen, Pomerantz, Mark, Harshman, Lauren C., Van Allen, Eliezer M., Wei, Xiao X., McGregor, Bradley, Choudhury, Atish D., Preston, Mark A., Dong, Fei, Signoretti, Sabina, Lindeman, Neal I., Bellmunt, Joaquim, Choueiri, Toni K., Sonpavde, Guru, Kwiatkowski, David J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028947/ https://www.ncbi.nlm.nih.gov/pubmed/31857723 http://dx.doi.org/10.1038/s41416-019-0686-0

Ejemplares similares

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma
por: Mullane, Stephanie A., et al.
Publicado: (2016)

Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy
por: Bellmunt, Joaquim, et al.
Publicado: (2016)

Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma
por: Nassar, Amin H., et al.
Publicado: (2019)

Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors
por: Nuzzo, Pier Vitale, et al.
Publicado: (2020)

Somatic ERCC2 Mutations Are Associated with a Distinct Genomic Signature in Urothelial Tumors
por: Kim, Jaegil, et al.
Publicado: (2016)

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma
por: Adib, Elio, et al.
Publicado: (2021)

The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine
por: Harshman, L C, et al.
Publicado: (2013)

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
por: Martini, Dylan J., et al.
Publicado: (2017)

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2018)

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
por: Powles, Thomas, et al.
Publicado: (2015)

Identification of ALK Gene Alterations in Urothelial Carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2014)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Kumar, Utpal, et al.
Publicado: (2021)

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
por: Rosenberg, Jonathan E., et al.
Publicado: (2018)

Precision Medicine to Treat Urothelial Carcinoma—The Way Forward
por: Luceno, Carvy Floyd, et al.
Publicado: (2023)

Urothelial carcinoma management in elderly or unfit patients()
por: Bellmunt, Joaquim, et al.
Publicado: (2016)

Studies in CRISPR-generated Mediterranean G6PD variant rats reveal G6PD orchestrates genome-wide DNA methylation and gene expression in vascular wall
por: Signoretti, Christina, et al.
Publicado: (2023)

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression
por: Lalani, Aly-Khan A., et al.
Publicado: (2017)

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
por: Pathak, Ranjan, et al.
Publicado: (2020)

Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors
por: Bellmunt, Joaquim, et al.
Publicado: (2015)

Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis
por: Liu, Junqi, et al.
Publicado: (2018)

The Relationship Between PD-1(rs2227981) and PD-L1(rs2890658) Polymorphisms and Urothelial Cell Carcinoma
por: Hlaing, Sa Tin Myo, et al.
Publicado: (2023)

Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
por: Tosev, Georgi, et al.
Publicado: (2021)

Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis
por: Liu, Haoran, et al.
Publicado: (2020)

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
por: Lalani, Aly-Khan A., et al.
Publicado: (2018)

Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma(1)
por: Leiter, Amanda, et al.
Publicado: (2016)

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
por: Stenehjem, David D, et al.
Publicado: (2018)

Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma
por: Tomiyama, Eisuke, et al.
Publicado: (2020)

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes
por: Grivas, Petros, et al.
Publicado: (2018)

Upper tract urothelial carcinoma: a different disease entity in terms of management
por: Leow, Jeffrey J, et al.
Publicado: (2017)

Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma
por: Sonpavde, G, et al.
Publicado: (2012)

PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis
por: Tan, Wei Phin, et al.
Publicado: (2019)

From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation
por: Mouw, Kent W., et al.
Publicado: (2018)

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
por: Sweis, Randy F., et al.
Publicado: (2018)

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
por: Wang, Li, et al.
Publicado: (2018)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
por: Faiena, Izak, et al.
Publicado: (2018)

Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis
por: Ding, Xiangli, et al.
Publicado: (2019)

Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer
por: Zeng, Dongqiang, et al.
Publicado: (2020)

Publisher Correction: Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
por: Tosev, Georgi, et al.
Publicado: (2021)

Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma
por: Shibata, Yosuke, et al.
Publicado: (2023)

Alterations of DNA damage response genes correlate with response and overall survival in anti‐PD‐1/PD‐L1‐treated advanced urothelial cancer
por: Joshi, Monika, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_htf80kcn8bgbriq4oco1tijove